Rewind Therapeutics, which is developing therapies for myelin-related diseases like MS, secured $18.3m in a Boehringer Ingelheim and Merck Group-backed round.
Rewind Therapeutics, a Belgium-based developer of treatments for myelin-related diseases, completed a €15.2m ($18.3m) series A round yesterday that was co-led by subsidiaries of pharmaceutical firms Boehringer Ingelheim and Merck Group.
Boehringer Ingelheim Venture Fund and Merck Ventures co-led the round with PMV, an investment firm owned by the Flemish government.
KU Leuven, the university from which Rewind spun out, took part in the round through its Centre for Drug Design and Discovery (CD3) as well as KU Leuven Gemma…
